Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications

Immunomodulatory monoclonal antibodies (mAbs) differ from their tumor-targeting counterparts because they exert therapeutic effects by directly interacting with soluble or (most often) cellular components of the immune system. Besides holding promise for the treatment of autoimmune and inflammatory...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Buqué, Aitziber, Bloy, Norma, Aranda, Fernando, Castoldi, Francesca, Eggermont, Alexander, Cremer, Isabelle, Fridman, Wolf Hervé, Fucikova, Jitka, Galon, Jérôme, Marabelle, Aurélien, Spisek, Radek, Tartour, Eric, Zitvogel, Laurence, Kroemer, Guido, Galluzzi, Lorenzo
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2015
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4485728/
https://ncbi.nlm.nih.gov/pubmed/26137403
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1008814
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados